Between 1998 and 2004, Merck employed several schemes with doctors and hospitals to defraud Medicaid and maintain market share for Vioxx®, the discontinued arthritis drug, and Zocor®, the statin whose patent protection expired in 2006, it was alleged.
When Dean Steinke, a Merck district sales manager, was unable to get management to stop its improper drug marketing tactics, he brought evidence to a team of experienced qui tam whistleblower attorneys. They took his case under seal to federal and state Governments.
After seven years of investigation and litigation, it was settled today, returning more than $400 million to federal and state taxpayers.
Read More